Erfurt Stefan, Hoffmeister Meike, Oess Stefanie, Asmus Katharina, Ritter Oliver, Patschan Susann, Patschan Daniel
Department of Medicine 1, University Hospital Brandenburg, Medical School (MHB) Theodor Fontane, Brandenburg - Germany.
Institute of Biochemistry, Brandenburg Medical School (MHB) Theodor Fontane, Brandenburg - Germany.
J Circ Biomark. 2021 Nov 30;10:20-25. doi: 10.33393/jcb.2021.2327. eCollection 2021 Jan-Dec.
Interleukin-33 (IL-33), a member of the IL-1 family, is critically involved in the modulation of the activity of a diverse range of immunocompetent cells. Essential roles have been implicated in cardioprotection, in both innate and adaptive immune responses in mucosal organs, and in the maintenance of adipose tissue cells. Over the past 10 years, several studies evaluated the usability of IL-33 as a biomarker in diseases of inflammatory and noninflammatory origin. Our group is currently evaluating the predictive role of serum IL-33 in acute kidney injury (AKI). The aim of the article is to discuss selected studies on IL-33 in different diseases and its potential role as a biomarker molecule.
白细胞介素-33（IL-33）是白细胞介素-1家族的成员，在多种免疫活性细胞活性的调节中起关键作用。它在心脏保护、黏膜器官的固有免疫和适应性免疫反应以及脂肪组织细胞的维持中都具有重要作用。在过去10年中，多项研究评估了IL-33作为炎症性和非炎症性疾病生物标志物的可用性。我们的团队目前正在评估血清IL-33在急性肾损伤（AKI）中的预测作用。本文的目的是讨论关于IL-33在不同疾病中的选定研究及其作为生物标志物分子的潜在作用。
